Home › Chronic Inflammatory Demyelinating Polyradiculoneuropathy › California › San Francisco
Chronic Inflammatory Demyelinating Polyradiculoneuropathy clinical trials in San Francisco, CA
4 studies for Chronic Inflammatory Demyelinating Polyradiculoneuropathy are looking for participants at sites in and around San Francisco (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
RecruitingPhase 2
- Site Number -1608, San Francisco
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
RecruitingPhase 3
- Clinical Study Site, San Francisco
- Clinical Study Site, San Francisco
A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
RecruitingPhase 2
- California Pacific Medical Center, San Francisco
A Study of HyQvia in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in Routine Clinical Care
RecruitingObservational study
- Neuro/Psych Sleep Clinic, San Francisco
Chronic Inflammatory Demyelinating Polyradiculoneuropathy trials in other cities
- New York City, NY7 studies
- Houston, TX6 studies
- Miami, FL6 studies
- St. Louis, MO5 studies
- New Haven, CT5 studies
- Kansas City, KS5 studies
- Indio, CA5 studies
- Philadelphia, PA5 studies
- Birmingham, AL4 studies
- Tampa, FL4 studies
- Orlando, FL4 studies
- Washington, DC4 studies
Other studies in San Francisco
- Prostate Cancer45 studies
- Breast Cancer43 studies
- Non-Small Cell Lung Cancer36 studies
- Cancer (all types)35 studies
- Heart Failure29 studies
- Metastatic Cancer28 studies
- Lung Cancer22 studies
- Melanoma22 studies
- Pancreatic Cancer20 studies
- Ovarian Cancer19 studies
- Colorectal Cancer18 studies
- Cardiovascular Disease18 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.